Clinical trial
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on…
NCT00479037 · Nycomed, Industry · Completed
Key facts
| NCT number | NCT00479037 |
|---|---|
| Title | Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) |
| Official title | A 24-week, International, Multi Centre, Randomised, Open Label, Parallel Group, Phase IV Clinical Trial Investigating Changes in Bone Formation Markers in Postmenopausal Women With Primary Osteoporosis Treated With Either PTH(1-84) or Strontium Ranelate |
| Lead sponsor | Nycomed, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Full Length Parathyroid Hormone, PTH(1-84), Strontium Ranelate |
| Enrollment | 82 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | May 25, 2007 |
| Last update posted | May 8, 2012 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: